drug_type
RELEVANT_DRUG
intervention_type
CAR T-cell therapy (gene-modified cellular immunotherapy)
drug_description
Autologous T cells lentivirally engineered to express an anti-CD38 chimeric antigen receptor with CD3ΞΆ activation and 4-1BB (TNFRSF9) costimulatory domains; targets CD38 on malignant cells to induce T-cell activation, proliferation, and cytotoxic killing.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are lentivirally engineered to express an anti-CD38 chimeric antigen receptor with CD3-zeta activation and 4-1BB costimulatory domains. Binding to CD38 on malignant cells triggers T-cell activation, proliferation, cytokine release, and perforin/granzyme-mediated cytotoxic killing, while 4-1BB enhances T-cell persistence and survival.
drug_name
CART-38
nct_id_drug_ref
NCT05442580